| Home | ||
| About us | ||
| Products | ||
| Patents | ||
| Claims | ||
| Case Reports | ||
| Case Report No. 14 | ||
| Patent Applications filed | ||
| Inquiry | ||
| Contact | ||
| German | ||
| Arabian | ||
| Japanese | ||
| Impressum | ||
Enclosure A)
** Please try to understand that for the
present we would like to provide you with nonconfidential information. After
having closed a secrecy agreement we will give you further and confidential
information
Contact
The international preliminary examination of the application by the European Patent Office has shown the following results: All claims possess novelty and industrial applicability. The claims 2, 3, 5, 6, 7, and 11 - 16 involve an inventive step. |
||
|
1.
|
Use of ______**__________, ______________ salt(s), their derivatives and/or decomposition products for the treatment of affections of the skin and of the mucous membrane as well as organs and tissues with the exception of the treatment of retrovirus (HIV) affections, and the disinfection. | |
|
2.
|
Use in accordance with claim 1, characterised in that the affections affect the skin and the mucous membranes. | |
|
3.
|
|
|
|
4.
|
Use in accordance with one of claims 1 to 3, characterised in that the affects and/or efflorescences may be caused by micro-organisms or accompanied by micro-organisms. | |
|
5.
|
Use in accordance with one of claims 1 to 4, characterised in that said affects represent parasitic affections, in particular scabies, pediculosis or creeping eruption. | |
|
6.
|
Use in accordance with at least one of the above claims, characterised in that the affections concern: | |
|
a) |
the eye, in
particular the eyelid, conjunctiva or cornea of the eye; the ear, in particular the outer ear; the nose, in particular the nasal cavity; the lips and the mucous membrane of the mouth and/or the tongue the vulva and/or the vagina; the penis, in particular the glans penis and the prepuce; the anus; the nail, in particular the nail bed, the perionychium and the nail groove as well as the nail-root; the hair, in particular the hair follicles and the sebaceous glands; and hands and feet, in particular finger and toe interstices. |
|
|
7.
|
Use in accordance with at least one of the above claims, characterised in that the __________, ___________ salts, their derivatives and/or decomposition products are present in the employed base in an amount of approximately 0.1 to 20 % by weight, preferably approximately 5 to 15 % by weight, in particular approximately 8 to 12 % by weight. | |
|
8.
|
Use in accordance with at least one of the above claims, characterised in that a __________ salt, in particular ____________, is employed. | |
|
9.
|
Use in accordance with at least one of the above claims, characterised in that the base is a liquid, half-solid or solid aqueous or non-aqueous galenic preparation. | |
|
10.
|
Use in accordance with claim 9, characterised in that the base represents an ointment, a gel, a cream, a paste, a suppository such as a vaginal suppository, a plaster, a tablet such as an effervescent tablet or a vaginal tablet, or a capsule, a pin, a powder, a solution, an aerosol, a two-component system or a suspension, such as a shake-mixture/dry-suspension. | |
|
11.
|
Use in accordance with claim 9 or 10, characterised in that the base is a dosing aerosol or a dosing solution. | |
|
12.
|
Use in accordance with claim 9 or 10, characterised in that the base is a bathing additive. | |
|
13.
|
Use in accordance with claim 9 or 10, characterised in that the ointment is an oil-in-water or a water-in-oil emulsion ointment. | |
|
14.
|
Use according to at least one of the above claims, characterised in that the base is a cortisone-containing preparation which comprises the _____________, ____________ salt(s), their derivatives and/or decomposition products in an amount of approximately 0.1 to 20 % by weight. | |
|
15.
|
Use in accordance with claim 9 or 10, characterised in that the base is a gel in which the _______________, _____________ salt(s), their derivatives and/or their decomposition products are present in an amount of approximately 0.1 to 5 % by weight, in particular approximately 0.1 to 2 % by weight. | |
|
16.
|
Use in accordance with claim 9 or 10, characterised in that the bathing additive is used in the form of a powder or a bathing salt tablet or an effervescent tablet, which is used in a concentration of approximately 0.1 to 1 % by weight in water. | |
 |
 |
 |